










Patients with ventricular arrhythmias.




- If symptoms do *NOT* suggest sustained arrhythmias.
- If baseline *ECG* and *echocardiogram* are normal.

The risk for sudden death *should be small*, but the evidence supporting this statement is limited.

There is *NO EVIDENCE* to support aggressive approach or antiarrhythmic therapy.







Polymorphic ventricular arrhythmias without organic heart disease

Catecholaminergic polymorphic VT

Congenital long QT syndromes

Idiopathic ventricular fibrillation


- with RBBB and ST
- with normal ECG

Catecholamine-dependent polymorphic VT



- Age: 8 ± 4 years.
- Male/female = 1.3/1
- Family history ++
- Stress related symptoms +++

Coumel. *Br Heart J* 1978. Leenhardt. *Circulation* 1995.

- Autosomal dominant: 2 families (33 ± 15 years) linked to chromosome 1q42-q43. Swan, *JACC* 1999
- RyR2 (the gene responsible for calcium release from sarcoplasmic reticulum). Priori, *Circulation* 2000
- CASQ2 (the gene for calsequestrin, the calcium reservoir in sarcoplasmic reticulum). Lahat, *Circulation* 2001




Bidirectional tachycardia in catecholaminergic VT




**Evaluation of exercise-induced syncope...
don't try this at home**














**Female, age 32.
Referred for "asymptomatic arrhythmias"**















The long QT syndrome and torsade de pointes











Questionable Brugada syndrome: Diagnostic approach

1. History: syncope?, epilepsy?, familial history?

2. ECG:

- Repeated traces.
- ECG with high V1-V2.

2. Holter:


- Short-coupled PVCs

3. Flecainide test.

4. Genetic screening.

5. Electrophysiologic study.


Effects of precordial electrode position on Brugada sign



Sodium channel blockers unmask a Brugada sign in patients with the SCN5A mutation


SCN5A mutation

Control



Brugada, *Circulation* 2000

Drug-induced changes in 12 patients with Brugada syndrome (VF) and 10 healthy controls.



Shimizu, *JCE* 2000

Brugada syndrome: Proarrhythmia during drug challenge



Morita, *JACC* 2003.

Brugada syndrome: electrophysiologic studies.

